Hepatology research : the official journal of the Japan Society of Hepatology · 2025
Tamoxifen-Induced Liver Injury in Patients With Breast Cancer: Frequency, Risk Factors and Clinical Course.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ueno Ayako, Ueno Masayuki, Nishikawa Mayo, Karai Mika, Imai Shiro, Kayahara Takahisa, Takabatake Hiroyuki, Morimoto Youichi, Yamaguchi Kazushige
Аннотация
AIM: Tamoxifen is a widely used endocrine treatment for breast cancer, also responsible for drug-induced steatotic liver diseases. This study aimed to investigate the frequency, clinical course and risk factors for tamoxifen-induced liver injury in patients with breast cancer.
METHODS: We conducted a retrospective analysis of 192 patients with breast cancer who initiated tamoxifen therapy between January 2008 and December 2017, undergoing blood tests and abdominal ultrasonography after receiving tamoxifen for at least 1 year. Liver injury was defined as alanine transaminase and/or alkaline phosphatase levels exceeding twice the upper limit of the normal range. We explored the risk factors for CTCAE grade ≥ 2 tamoxifen-induced liver injury and validated the results with a cohort of additional 166 patients.
RESULTS: Among the 192 patients, 30 (15.6%) experienced tamoxifen-induced liver injury, including 13 patients with grade ≥ 2 liver injury. Although most patients with grade 1 liver injury experienced spontaneous resolution, several patients with grade ≥ 2 liver injury required treatment interruption/discontinuation or developed persistent liver injury. Progression to cirrhosis was suspected in two (1.0%) patients. High body mass index (BMI), diabetes, dyslipidemia and pre-existing liver steatosis were significantly associated with an increased risk of grade ≥ 2 liver injury.
CONCLUSIONS: Tamoxifen-induced liver injury was observed in 15.6% of the patients. Metabolic factors, such as high BMI, diabetes, dyslipidemia and pre-existing liver steatosis, were considered potential predictors of CTCAE grade ≥ 2 liver injury. Collaboration with gastroenterologists should be encouraged in patients with grade ≥ 2 liver injuries, where spontaneous remission is uncommon.
METHODS: We conducted a retrospective analysis of 192 patients with breast cancer who initiated tamoxifen therapy between January 2008 and December 2017, undergoing blood tests and abdominal ultrasonography after receiving tamoxifen for at least 1 year. Liver injury was defined as alanine transaminase and/or alkaline phosphatase levels exceeding twice the upper limit of the normal range. We explored the risk factors for CTCAE grade ≥ 2 tamoxifen-induced liver injury and validated the results with a cohort of additional 166 patients.
RESULTS: Among the 192 patients, 30 (15.6%) experienced tamoxifen-induced liver injury, including 13 patients with grade ≥ 2 liver injury. Although most patients with grade 1 liver injury experienced spontaneous resolution, several patients with grade ≥ 2 liver injury required treatment interruption/discontinuation or developed persistent liver injury. Progression to cirrhosis was suspected in two (1.0%) patients. High body mass index (BMI), diabetes, dyslipidemia and pre-existing liver steatosis were significantly associated with an increased risk of grade ≥ 2 liver injury.
CONCLUSIONS: Tamoxifen-induced liver injury was observed in 15.6% of the patients. Metabolic factors, such as high BMI, diabetes, dyslipidemia and pre-existing liver steatosis, were considered potential predictors of CTCAE grade ≥ 2 liver injury. Collaboration with gastroenterologists should be encouraged in patients with grade ≥ 2 liver injuries, where spontaneous remission is uncommon.